Oasmia Pharmaceutical AB (publ) (OTCMKTS:OASMY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Monday, Zacks.com reports. The brokerage presently has a $1.50 price objective on the stock. Zacks Investment Research‘s price target points to a potential upside of 12.36% from the stock’s current price.
According to Zacks, “Oasmia Pharmaceutical AB is a pharmaceutical company which develops and manufactures drugs for human and veterinary oncology. Its drugs portfolio comprises Paclical, Doxophos, Docecal and OAS-19, for human treatment as well as Paccal Vet-CA1 and Doxophos Vet, for cancer treatment in dogs, which are in different clinical phases. Oasmia Pharmaceutical AB is based in Uppsala, Sweden. “
Shares of OTCMKTS OASMY opened at $1.34 on Monday. The firm has a market cap of $199.53 million, a PE ratio of -22.25 and a beta of 0.22. Oasmia Pharmaceutical AB has a 12-month low of $1.09 and a 12-month high of $2.44. The company’s fifty day simple moving average is $1.16 and its 200 day simple moving average is $1.33. The company has a quick ratio of 2.08, a current ratio of 2.33 and a debt-to-equity ratio of 0.01.
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea/Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer; and Docetaxel micellar, a patented formulation of cytostatic docetaxel in combination with XR-17 that has completed pre-clinical trial for the treatment of prostate cancer.
Recommended Story: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oasmia Pharmaceutical AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oasmia Pharmaceutical AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.